B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg… - Annals of the …, 2022 - ard.bmj.com
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …
被引用次数：218 相关文章
[PDF] bmj.com

[PDF][PDF] B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg… - Annals of the …, 2021 - ard.bmj.com
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino… - Annals of the …, 2022 - search.proquest.com
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg, BH Rovin… - 2022 - pubmed.ncbi.nlm.nih.gov
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …
[PDF] sfndt.org

[PDF][PDF] B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg, BH Rovin… - Ann Rheum Dis, 2022 - sfndt.org
L'incidence de l'insuffisance rénale chronique terminale dans la néphropathie lupique
proliférative a grandement diminué à partir de 1980 avec la généralisation de l'usage des …

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino… - Annals of the …, 2022 - ohiostate.elsevierpure.com
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …
[HTML] nih.gov

[HTML][HTML] B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg… - Annals of the …, 2022 - ncbi.nlm.nih.gov
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

RA Furie, G Aroca, MD Cascino, JP Garg… - Annals of the …, 2021 - europepmc.org
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …
[PDF] academia.edu

[PDF][PDF] B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg, BH Rovin… - academia.edu
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …
[PDF] sfndt.org

[PDF][PDF] B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

RA Furie, G Aroca, MD Cascino, JP Garg… - Ann Rheum …, 2022 - adhesion.sfndt.org
L'incidence de l'insuffisance rénale chronique terminale dans la néphropathie lupique
proliférative a grandement diminué à partir de 1980 avec la généralisation de l'usage des …